Log in

NASDAQ:CLLS - Cellectis Stock Price, Forecast & News

$18.77
+0.18 (+0.97 %)
(As of 02/21/2020 08:00 AM ET)
Today's Range
$18.44
Now: $18.77
$18.83
50-Day Range
$15.47
MA: $17.29
$18.77
52-Week Range
$9.50
Now: $18.77
$20.84
Volume96,365 shs
Average Volume94,171 shs
Market Capitalization$796.79 million
P/E RatioN/A
Dividend YieldN/A
Beta1.89
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLLS
CUSIPN/A
Phone33-1-81-69-16-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.43 million
Book Value$10.82 per share

Profitability

Net Income$-78,690,000.00
Net Margins-446.75%

Miscellaneous

Employees161
Market Cap$796.79 million
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.


Cellectis (NASDAQ:CLLS) Frequently Asked Questions

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

How were Cellectis' earnings last quarter?

Cellectis SA (NASDAQ:CLLS) posted its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.18. The biotechnology company had revenue of $2.93 million for the quarter, compared to the consensus estimate of $3.45 million. Cellectis had a negative return on equity of 21.03% and a negative net margin of 446.75%. View Cellectis' Earnings History.

When is Cellectis' next earnings date?

Cellectis is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Cellectis.

What price target have analysts set for CLLS?

6 brokerages have issued 12 month target prices for Cellectis' stock. Their forecasts range from $20.00 to $73.00. On average, they anticipate Cellectis' share price to reach $40.80 in the next year. This suggests a possible upside of 117.4% from the stock's current price. View Analyst Price Targets for Cellectis.

What is the consensus analysts' recommendation for Cellectis?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectis.

Has Cellectis been receiving favorable news coverage?

News articles about CLLS stock have trended somewhat positive this week, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cellectis earned a news impact score of 1.3 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Cellectis.

Are investors shorting Cellectis?

Cellectis saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 226,800 shares, a drop of 7.5% from the January 15th total of 245,100 shares. Based on an average daily volume of 134,600 shares, the short-interest ratio is presently 1.7 days. Approximately 0.5% of the shares of the company are short sold. View Cellectis' Current Options Chain.

Who are some of Cellectis' key competitors?

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Exelixis (EXEL), Editas Medicine (EDIT), WEC Energy Group (WEC), Micron Technology (MU), Neurocrine Biosciences (NBIX) and Portola Pharmaceuticals (PTLA).

Who are Cellectis' key executives?

Cellectis' management team includes the folowing people:
  • Dr. André Choulika, Co-Founder, Chairman & CEO (Age 54)
  • Dr. David J. D. Sourdive, Co-Founder, Deputy CEO, Exec. VP of Technical Operations & Director (Age 52)
  • Mr. Eric Dutang, Chief Financial Officer (Age 45)
  • Ms. Elsy Boglioli, Chief Operating Officer (Age 37)
  • Mr. Jean Charles Epinat, Chief Technological Officer

When did Cellectis IPO?

(CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Who are Cellectis' major shareholders?

Cellectis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (7.50%), ARK Investment Management LLC (3.16%), Nikko Asset Management Americas Inc. (3.01%), Sumitomo Mitsui Trust Holdings Inc. (3.01%), Capital International Investors (2.39%) and Credit Suisse AG (1.09%).

Which institutional investors are selling Cellectis stock?

CLLS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., UBS Group AG, Cubist Systematic Strategies LLC, Victory Capital Management Inc. and Eqis Capital Management Inc..

Which institutional investors are buying Cellectis stock?

CLLS stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Rhenman & Partners Asset Management AB, ARK Investment Management LLC, Capital Asset Advisory Services LLC, Geode Capital Management LLC, Atria Investments LLC, OneAscent Financial Services LLC and Granite Point Capital Management L.P..

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $18.77.

How big of a company is Cellectis?

Cellectis has a market capitalization of $796.79 million and generates $21.43 million in revenue each year. The biotechnology company earns $-78,690,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Cellectis employs 161 workers across the globe.View Additional Information About Cellectis.

What is Cellectis' official website?

The official website for Cellectis is http://www.cellectis.com/.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]


MarketBeat Community Rating for Cellectis (NASDAQ CLLS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  359 (Vote Outperform)
Underperform Votes:  243 (Vote Underperform)
Total Votes:  602
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel